Drugs / SC-CAR.GPC3xIL15.21 CAR T cells
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07224568 | Apr 2026 → Aug 2030 expected | hepatocellular carcinoma, liposarcoma, rhabdomyosarcoma, yolk sac tumor | Seattle Children's Hospital | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07148050 | Dec 2025 → Apr 2029 expected | Wilms tumor, hepatoblastoma, liposarcoma, rhabdoid tumor +3 | Seattle Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SC-CAR.GPC3xIL15.21 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07224568 ↗ |
| Known as | GPC3xIL15.21 | “This research study will use these cells (named GPC3xIL15.21) to treat patients with solid tumors that express GPC3 on their surface.” NCT07148050 ↗ |
| Known as | GPC3xIL15.21 CAR T cells | “The GPC3xIL15.21 CAR T cells are an investigational product and have not been approved by the Food and Drug Administration.” NCT07148050 ↗ |
| Action | Deplete | “This study is testing a different treatment which uses the body's own immune system to recognize and kill the cancer cells, called chimeric antigen receptor (CAR) T cells.” NCT07148050 ↗ |
| Modality | Cell therapy | “genetically modified to co-express a GPC3-specific chimeric antigen receptor (CAR), interleukin (IL)-15 and IL-21” NCT07148050 ↗ |
| Route | Intravenous | “followed by CAR T cell infusion IV” NCT07148050 ↗ |
| Target | GPC3 | “We will insert a gene that will program the CAR T cell to recognize GPC3” NCT07148050 ↗ |